Trial reportJournal of neurology2005
Pharmacotherapy of Parkinson's disease in Germany.
Trial report in Journal of neurology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Conscious vision: investigating visual hallucination awareness in Lewy body disease.Brain communications · 2026Article
- Effects of specialised physiotherapy on mortality in Parkinson's disease: a prospective observational study.NPJ Parkinson's disease · 2025Article
- Distinct grey and white matter changes are associated with the phenomenology of visual hallucinations in Lewy Body Disease.Scientific reports · 2024Article
- Visual hallucinations in Lewy body disease: pathophysiological insights from phenomenology.Journal of neurology · 2022Article
- Review of medicine utilization for Parkinson's disease management: the Bulgarian perspective.Journal of public health research · 2021Article
- Gut and Vagina Microbiota Associated With Estrus Return of Weaning Sows and Its Correlation With the Changes in Serum Metabolites.Frontiers in microbiology · 2021Article
- Therapeutic strategies in the early stages of Parkinson's disease: a cross-sectional evaluation of 15 years' experience with a large cohort of Romanian patients.Neuropsychiatric disease and treatment · 2019Article
- Profile Of Patients With Advanced Parkinson's disease Suitable For Device-Aided Therapies: Restrospective Data Of A Large Cohort Of Romanian Patients.Neuropsychiatric disease and treatment · 2019Article
- Depression and Catechol-O-methyltransferase (COMT) genetic variants are associated with pain in Parkinson's disease.Scientific reports · 2017Article
- Pathophysiology of Small-Fiber Sensory System in Parkinson's Disease: Skin Innervation and Contact Heat Evoked Potential.Medicine · 2016Article
- Article
- [Dementia and depression determine care dependency in Parkinson's disease: analysis of 1,449 outpatients receiving nursing care in Germany].Der Nervenarzt · 2011Article
- Do neurologists in Germany adhere to the national Parkinson's disease guideline?Neuropsychiatric disease and treatment · 2011Article
- Medication responsiveness of motor symptoms in a population-based study of Parkinson disease.Parkinson's disease · 2011Article
- [Direct costs for Parkinson's treatment in private neurology practices in Berlin].Der Nervenarzt · 2009Article
- Article
- The four As associated with pathological Parkinson disease gamblers: anxiety, anger, age, and agonists.Neuropsychiatric disease and treatment · 2007Article
- Treatment of Parkinson's disease: a survey of patients and neurologists.Clinical drug investigation · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment standards or guidelines have been developed for most features of Parkinson's disease (PD). However, data on the actual treatment that is put into practice are scarce. In 2000, a nationwide survey on the topic of sudden onset of sleep (SOS) in PD was initiated among the members of the German patient support group (deutsche Parkinson-Vereinigung, dPV). A part of this mailed questionnaire survey covering the antiparkinsonian and concomitant medication of the participants is presented here. This study analyses data sets from more than 6,500 PD patients. The mean dopaminergic dose was equivalent to 599 +/- 387 mg levodopa/die. The most frequently administered drugs were levodopa (94.2 %), dopamine agonists (DA) (71.7 %), amantadine (40.1 %), selegiline (27.6 %), entacapone (20.4 %), budipine (12.3 %), and anticholinergics (11.8 %). Costs of pharmacotherapy were estimated to be approximately <euro> 399 million/year in Germany. PD drug therapy in general strongly depended on age, disease duration, and the level of care. The treatment guidelines were apparently not consistently followed underlining the need for their continuous propagation throughout the medical community. In addition our data suggest that non-motor symptoms in PD are not adequately treated and that concomitant sedative medication contributes to the occurrence of SOS.
Indexed as
Identifiers
15765268What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.